NASDAQ:IDYA

Ideaya Biosciences Stock Insider Trading

etoro logo Buy IDYA
*Your capital is at risk
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026

IDEAYA Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.2M and sold 407K IDYA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 6.2M shares
Sell 407K shares
82% Buy Activity
Weak Negative Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Beaupre Darrin
Chief Medical Officer
Officer 185 000
Value: $3.74M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Dorman Stuart
Chief Commercial Officer
Officer 15 000
Value: $303.6K
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Ruiz Briseno Andres
See Remarks
Officer 75 000
Value: $1.52M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
White Michael Anthony
Chief Scientific Officer
Officer 185 000
Value: $3.74M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Snyder Douglas B.
SVP, General Counsel
Officer 33 000
Value: $667.9K
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Hata Yujiro S
President And CEO
CEO / President 600 000
Value: $12.1M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Hata Yujiro S
President And CEO
CEO / President 600 000
Value: $12.1M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Snyder Douglas B.
SVP, General Counsel
Officer 33 000
Value: $667.9K
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
White Michael Anthony
Chief Scientific Officer
Officer 185 000
Value: $3.74M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Ruiz Briseno Andres
See Remarks
Officer 75 000
Value: $1.52M
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Dorman Stuart
Chief Commercial Officer
Officer 15 000
Value: $303.6K
Feb 27, 2025
Buy
Stock Option (right to buy)
A-Award
Beaupre Darrin
Chief Medical Officer
Officer 185 000
Value: $3.74M
Feb 18, 2025
Buy
Common Stock
M-Exempt
Hata Yujiro S
President And CEO
CEO / President 12 808
Value: $250.0K
Feb 18, 2025
Buy
Stock Option (right to buy)
M-Exempt
Hata Yujiro S
President And CEO
CEO / President 12 808
Value: $250.0K
Feb 18, 2025
Buy
Stock Option (right to buy)
M-Exempt
Hata Yujiro S
President And CEO
CEO / President 12 808
Value: $250.0K
Feb 18, 2025
Buy
Common Stock
M-Exempt
Hata Yujiro S
President And CEO
CEO / President 12 808
Value: $250.0K
Dec 11, 2024
Buy
Stock Option (Right to Buy)
Dorman Stuart
Chief Commercial Officer
Officer 170 000
Value: $4.67M
Dec 11, 2024
Buy
Stock Option (Right to Buy)
Dorman Stuart
Chief Commercial Officer
Officer 170 000
Value: $4.67M
Nov 29, 2024
Buy
Common Stock
A-Award
Ruiz Briseno Andres
See Remarks
Officer 682
Value: $15.9K
Sep 26, 2024
Buy
Stock Option (Right to Buy)
A-Award
Snyder Douglas B.
SVP, General Counsel
Officer 140 000
Value: $4.27M
Sep 26, 2024
Buy
Stock Option (Right to Buy)
A-Award
Snyder Douglas B.
SVP, General Counsel
Officer 140 000
Value: $4.27M
Sep 18, 2024
Buy
Common Stock
J-Other
Snyder Douglas B.
Insider
Other 0
Value: $0
Sep 18, 2024
Buy
Common Stock
J-Other
Snyder Douglas B.
Insider
Other 0
Value: $0
Jun 27, 2024
Buy
Common Stock
M-Exempt
Throne Jason
Chief Legal Officer
Officer 47 060
Value: $329.9K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
M-Exempt
Throne Jason
Chief Legal Officer
Officer 6 424
Value: $85.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT IDEAYA BIOSCIENCES INC.
IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE